Yield10 Bioscience Reports Promising Seed Yield Results for Novel Yield Trait C3004 in Growth Chamber Studies in Camelina
September 05 2018 - 8:00AM
Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new
technologies to create step-change improvements in crop yield to
enhance global food security, today announced promising results for
its novel yield trait C3004 in growth chamber studies conducted
using its Camelina platform. Camelina plant lines containing C3004
grew vigorously, and the best lines produced increases in seed
yield in a range of 26% to 65% as compared to control plants.
Yield10 plans to conduct field tests of the C3004 trait in Camelina
as part of its 2019 Field Test program in Canada. In addition,
Yield10 is fast tracking deployment of the C3004 trait into canola
and soybean to determine if the trait produces similar effects on
plant vigor and seed yield in major oilseed crops.
“Our early research results with C3004 in Camelina including
plant growth and vigor, branching and seed yield, though
preliminary, are very encouraging,” said Kristi Snell, Ph.D., Chief
Science Officer of Yield10 Bioscience. “These initial seed yield
data for C3004 suggest we can harness the metabolic machinery of
plants to drive robust increases in seed yield in Camelina. The
next step is to determine if the effects of C3004 on plant vigor
and seed yield can be successfully achieved in Camelina under field
conditions and translated into canola, soybean and other commercial
crops.”
Background on C3004 and Results
Yield10’s C3004 yield trait was identified as a gene that was
overexpressed in Camelina plants engineered to express C3003, a
trait based on a gene found in algae. While the role of C3004
is currently not well understood, it may have an effect on carbon
partitioning in plants and, under certain conditions, its effect
may potentially be additive with C3003, which impacts
photorespiration. Yield10 is researching the combination of C3003
and C3004 in Camelina.
Yield10 constructed C3004 to increase expression of the gene and
tested it in Camelina. Stable plant lines were produced and yield
studies were performed in a controlled environment growth chamber.
Yield10 reported that increased expression of C3004 in Camelina
resulted in a significant increase in plant growth and vigor,
increased seed yield, and in some cases increased individual seed
weight. In six Camelina plant lines containing C3004, average seed
yield (grams/plant) increased by 26% to 65% over control plants.
Tertiary branching was measured in a subset of plants, and the
increase in seed yield was accompanied by an increase in tertiary
branching.
Summary of Preliminary Results for Expression of C3004
in Camelina
Camelina Line |
% Increase in Seed Yield |
wild-type control |
--- |
OY03 (C3004+) |
26% |
OY04 (C3004+) |
41% |
OY12 (C3004+) |
52%* |
OY15 (C3004+) |
65%* |
OY16 (C3004+) |
46% |
OY17 (C3004+) |
53%* |
*statistically significant, Student’s t-test p<0.05.
Data average 3-4 plants per line.
Yield10 outlined a series of next steps in the Company’s
research with C3004 including,
- Test C3004 in Camelina in 2019 field tests
- Test C3004 in combination with C3003 in Camelina
- Fast-track deployment of the Camelina C3004 gene trait alone
and in combination with C3003 in canola and soybean
- Develop a strategy with C3004 to enable a path to non-regulated
yield traits under current USDA-APHIS rules
- Identify additional opportunities for collaboration in oilseeds
and other commercial crops
“Our metabolic engineering approach allows us to look at the
challenge of increasing seed yield differently, as we focus on the
capture, fixation and deposition of carbon from the air to seed,”
said Oliver Peoples, Ph.D., President and Chief Executive Officer
of Yield10. “Yield10’s early research which introduced a very
complex metabolic pathway into Camelina illustrates to us that a
doubling of seed yield or other similar high producing outcomes for
crop performance can be achieved, at least experimentally, in
plants. The results we are generating as we study the effects of
C3003 and C3004 are increasing our confidence that we can convert
our unique scientific approach and insights into the successful
development of step-change yield improvements in major
crops.”
About Yield10
Bioscience
Yield10 Bioscience, Inc. is focused on developing new
technologies to achieve step-change improvements in crop yield to
enhance global food security. Yield10 has an extensive track record
of innovation based around optimizing the flow of carbon in living
systems. Yield10 is leveraging its technology platforms and
unique knowledge base to design precise alterations to gene
activity and the flow of carbon in plants to produce higher yields
with lower inputs of land, water or fertilizer. Yield10 is
advancing several yield traits it has developed in crops such as
Camelina, canola, soybean and rice. Yield10 is headquartered in
Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon,
Canada.
For more information about the Company, please visit
www.yield10bio.com.
(YTEN-G)
Safe Harbor for Forward-Looking
Statements
This press release contains forward-looking statements which are
made pursuant to the safe harbor provisions of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. The forward-looking
statements in this release do not constitute guarantees of future
performance. Investors are cautioned that statements in this press
release which are not strictly historical, including, without
limitation, those relating to the timing for conduct of field
tests of the C3004 trait in Camelina, the ability to replicate data
from growth chamber studies in field tests, the ability to
translate the positive effects observed in the testing of C3004 in
Camelina to other crops, the potential to develop a non-regulated
version of C3004, and the ability to secure new collaborations or
licenses, constitute forward-looking statements. Such
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those anticipated, including the risks and uncertainties
detailed in Yield10 Bioscience's filings with the Securities and
Exchange Commission. Yield10 assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the matters described
herein.
Contacts: Yield10
Bioscience:Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Investor Relations: Amato and Partners,
LLCadmin@amatoandpartners.com
Media Inquiries: Eric FischgrundFischtank Marketing and
PReric@fischtankpr.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/7d89e842-787b-455c-8456-c5566c44bf10
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Yield10 Bioscience (NASDAQ:YTEN)
Historical Stock Chart
From Apr 2023 to Apr 2024